Health Care & Life Sciences » Pharmaceuticals | Innoviva Inc.

Innoviva Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
4,758.00
19,499.00
67,772.00
147,392.00
231,040.00
274,827
SG&A Expense
154,418.00
41,253.00
22,259.00
24,450.00
25,354.00
17,004
EBIT
157,863.00
33,929.00
-
108,988.00
191,704.00
243,951
Unusual Expense
1,000.00
3,800.00
-
2,342.00
15,356.00
11,445
Non Operating Income/Expense
3,268.00
528.00
1,120.00
40.00
214.00
43
Interest Expense
9,348.00
36,892.00
51,803.00
52,416.00
43,601.00
23,954
Pretax Income
170,701.00
73,530.00
18,760.00
59,536.00
134,272.00
210,255
Consolidated Net Income
170,701.00
73,530.00
18,760.00
59,536.00
134,272.00
406,328
Net Income
170,701.00
73,530.00
18,760.00
59,536.00
134,143.00
395,056
Net Income After Extraordinaries
170,701.00
21,404.00
18,760.00
59,536.00
134,143.00
395,056
Net Income Available to Common
170,701.00
168,464.00
18,760.00
59,536.00
134,143.00
395,056
EPS (Basic)
1.67
1.50
0.16
0.53
1.17
3.53
Basic Shares Outstanding
102,425.00
112,059.00
115,372.00
110,280.00
106,945.00
100,849
EPS (Diluted)
1.67
1.50
0.16
0.53
1.17
3.53
Diluted Shares Outstanding
102,425.00
112,059.00
115,372.00
123,233.00
119,866.00
113,408
EBITDA
149,660.00
21,754.00
45,513.00
122,942.00
205,686.00
257,823
Non-Operating Interest Income
778.00
563.00
343.00
582.00
1,311.00
1,660
Minority Interest Expense
-
-
-
-
129.00
11,272

About Innoviva

View Profile
Address
2000 Sierra Point Parkway
Brisbane California 94005
United States
Employees -
Website http://www.inva.com
Updated 07/08/2019
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.